Nateglinide

(Redirected from Starlix)

Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis.

Nateglinide
Clinical data
Trade namesStarlix
AHFS/Drugs.comMonograph
MedlinePlusa699057
License data
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding98%
Elimination half-life1.5 hours
Identifiers
  • (2R)-2-({[trans-4-(1-methylethyl)cyclohexyl]carbonyl}amino)-3-phenylpropanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.170.086 Edit this at Wikidata
Chemical and physical data
FormulaC19H27NO3
Molar mass317.429 g·mol−1
3D model (JSmol)
  • O=C(N[C@H](Cc1ccccc1)C(O)=O)[C@H]2CC[C@@H](CC2)C(C)C
  • InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1 checkY
  • Key:OELFLUMRDSZNSF-BRWVUGGUSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.

Pharmacology

edit

Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.

Contraindications

edit

Nateglinide is contraindicated in patients who:

Comparisons with other drugs for type 2 diabetes

edit

A study funded by Novo Nordisk, the U.S. distributor for Repaglinide, compared their product with Nateglinide in "A randomized, parallel-group, open-label, multicenter 16-week clinical trial".[1] They concluded that the two were similar, but "repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing HbA1c and FPG values after 16 weeks of therapy."

Dosage

edit

Nateglinide is delivered in 60 mg & 120 mg tablet form.

See also

edit

References

edit
  1. ^ Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM (June 2004). "Repaglinide versus nateglinide monotherapy: a randomized, multicenter study". Diabetes Care. 27 (6). American Diabetes Association: 1265–70. doi:10.2337/diacare.27.6.1265. PMID 15161773. Retrieved 2014-11-20.
edit